Literature DB >> 7534752

A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma.

M R Grever1, J Benedetti, S P Balcerzak, S A Taylor, T P Miller, S R Dakhil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7534752     DOI： 10.1007/bf00873969

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  5 in total

1.  Central nervous system toxicity with fludarabine.

Authors:  D E Merkel; N L Griffin; K Kagan-Hallet; D D Von Hoff
Journal:  Cancer Treat Rep       Date:  1986-12

2.  Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.

Authors:  M R Grever; K J Kopecky; C A Coltman; J C Files; B R Greenberg; J J Hutton; R Talley; D D Von Hoff; S P Balcerzak
Journal:  Nouv Rev Fr Hematol       Date:  1988

3.  A comprehensive phase I and II clinical investigation of fludarabine phosphate.

Authors:  M Grever; J Leiby; E Kraut; E Metz; J Neidhart; S Balcerzak; L Malspeis
Journal:  Semin Oncol       Date:  1990-10       Impact factor: 4.929

Review 4.  Phase I clinical trials with fludarabine phosphate.

Authors:  D D Von Hoff
Journal:  Semin Oncol       Date:  1990-10       Impact factor: 4.929

5.  Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.

Authors:  J M Leiby; K M Snider; E H Kraut; E N Metz; L Malspeis; M R Grever
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.